|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Other
Autoimmune Diseases Research &
Development
Our ongoing research in autoimmune diseases is primarily based
on cell trafficking and focuses on discovering disease-modifying
approaches to treating a wide range of autoimmune diseases,
including MS and CD. Tysabri emerged from this research
program. In 2007, we continued our research exploring novel
anti-inflammatory approaches through our collaboration with
Archemix Corp. (Archemix) in addition to our core alpha 4
integrin programs.
Since first publishing the hypothesis concerning the therapeutic
potential of blocking alpha 4 integrin in 1992, our scientists
have been expanding and refining our understanding of how cells
enter tissues. Through this deep understanding, we have
developed small molecules that can selectively block particular
alpha 4 integrin interactions. We have advanced two compounds in
this area, with ELND002 currently in Phase 1 and ELND004
expected to enter Phase 1 in the first half of 2008.
|
| |||||||
